How to manage immune-related adverse effects in lung cancer patients under immunotherapy

T.G. Blum (Berlin, Germany), D. Baldwin (Nottingham, United Kingdom)

Source: CME Online 2019
Number: 100027

CME test or case report

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T.G. Blum (Berlin, Germany), D. Baldwin (Nottingham, United Kingdom). How to manage immune-related adverse effects in lung cancer patients under immunotherapy. CME Online 2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Influenza and Pneumococcal vaccination effects on the immune-related adverse events in patients under immunotherapy for an advanced stage non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021

How to evaluate the immune status of lung cancer patients before immunotherapy
Source: Breathe, 13 (4) 291; 10.1183/20734735.001917
Year: 2017



Impact of antibiotics on immunotherapy response in lung cancer patients
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

Predictors of immunotherapy induced immune-related adverse events
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006

Re-challenge of immunotherapy in a lung cancer patient
Source: Virtual Congress 2021 – Lung cancer grand round
Year: 2021


Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004

The effects of different chemotherapy regimes in the patients with advanced lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 755s
Year: 2006

Cardiovascular effects of innovative therapies in lung cancer
Source: Eur Respir Monogr 2020; 88: 154-166
Year: 2020


Eosinophilia in lung cancer patients treated with immunotherapy
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021


Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



How to treat lung cancer in IPF patients
Source: Research Seminar 2015
Year: 2015

A bleeding problem in lung cancer patients
Source: Eur Respir J 2015; 45: 601-603
Year: 2015


A preliminary study on targeted therapies in advanced lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009

Common therapeutic approaches in IPF and lung cancer
Source: Research Seminar 2015
Year: 2015


The effect of nutritional indicators on prognosis of patients with advanced lung cancer
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Possible predictors of the bronchodilation test response within lung function assessment of patients with operable lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005